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eration was less evident than R lesions (grade;1.13±0.35 vs 2.17±0.75; P<0.01). 3) In
edge restenosis lesions, extracellular matrices were abundant, and they were composed
of coarse collagen fiber and abundant mucinous materials. In contrast, the major compo-
nent of extracellular matrices in the R lesions were finely fibrillar and dense collagen. 4)
Thrombi were not apparent in any edge restenosis or R lesions. Conclusions: Edge res-
tenosis following BT consisted of weak proliferation of myofibroblasts and abundant dep-
osition of extracellular matrices such as mucinous materials. It was not be accompanied
by inflammatory reaction or thrombosis. Edge restenosis following BT may be a patholog-
ically distinct entity.
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880-4 Intracoronary Brachytherapy Protects Bifurcation 
Lesions
Karsten Meyer, Ralf Koester, Jan Kaehler, Andreas Schuchert, Horst Thurmann, Manuel 
Todorovic, Winfried Alberti, Thomas Muenzel, Thomas Meinertz, Andreas Kruell, 
University of Hamburg, Hamburg, Germany
Background: Intracoronary brachytherapy frequently involves lesions from which side
branches originate. These side branches often contain proximal plaques raising the
question whether a bifurcation intervention is required. To date it is not clear whether
plaque progression at the origin of the side branch is arrested by the brachytherapy of the
main branch. In this study we analyzed the plaque progression in side branches of
lesions treated with intracoronary brachytherapy.
Methods: One hundred and fourty-six patients with in-stent-restenosis >70% in diameter
were treated with PTCA followed by intracoronary brachytherapy. Brachytherapy was per-
formed with the Betacath system (Novoste). Thirty-three patients had bifurcation lesions
involving a side branch of 1.7±0.4 mm in diameter, originating from the irradiated portion
of the LAD (n=20), LCX (n=5) or RCA (n=8). Five lesions in side branches were dilated
during bifurcation interventions. Brachytherapy was performed with 18.5±1.5 Gy for
199±35 seconds within the main vessel but not in the side branch. The lumen diameter of
the side branch was analyzed by quantitative coronary angiography (QCA) at the time of
intervention and at follow-up at 8.6±3.5 months.
Results: There was one asymptomatic side branch occlusion due to the procedure.
There were no in-hospital adverse events such as death, myocardial infarction or reinter-
vention. QCA revealed a side branch minimal lumen diameter of 1.3±0.6 mm at the time
of intervention and of 1.4±0,7 mm at follow-up corresponding to mean diameter stenoses
of 25.2±22.9% and 24.7±23.1% (p>0.05). At follow-up none of the dilated side branch
lesions had a binary diameter restenosis (>50%). There was no further side branch
occlusion and no adverse clinical event related to the side branch lesion.
Conclusion: Intracoronary brachytherapy appears to have a protective effect on the pro-
gression of lesions in side branch origins even if brachytherapy is only performed in the
main branch and not in the side branch.
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880-5 Optimizing Dosimetry With High Dose Intracoronary 
Gamma Radiation 21 Gy for Patients With Diffuse In-
Stent Restenosis
Ron Waksman, Rebecca Torguson, Ellen Pinnow, Donna J. Whitman, Afework 
GebreEyesus, Rosanna Chan, Eduard Cheneau, Andrew E. Ajani, Michael Porrazzo, 
Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Joseph Lindsay, Washington 
Hospital Center, Washington, DC
Background: The efficacy of coronary gamma radiation in preventing recurrent in-stent
restenosis (ISR) is established. Vascular brachytherapy (VBT) may be less effective with
the approved dose of 14 Gy. Previously we reported a better outcome with 18 Gy. We
sought to examine if escalation of the dose to 21 Gy is safe and improves efficacy.
Methods: 35 pts with diffuse ISR in native coronary arteries and saphenous vein grafts
(lesion length 20-80mm) underwent PCI, atherectomy, and/or additional stents. Post-
intervention pts were treated with gamma VBT using the Checkmate system (Cordis). A
ribbon with 14-23 seeds was positioned to cover the treated segment and adequate mar-
gins, with a mean length of 63 ± 8mm. The prescribed dose was 21 Gy at 2mm. All pts
were discharged with Clopidogrel for 12 mo. 6-mo clinical outcomes were compared to
120 pts treated with 14 Gy and 120 pts treated with 18 Gy, both groups treated with at
least 6 mo of Clopidogrel. 
Results: High dose of 21 Gy was associated with prolonged dwell time of 28.6 + 2.9 min,
but with absence of procedural or in-hospital complications, when compared with lower
doses. At 6 mo there was significant reduction in the need for repeat target lesion revas-
cularization in the pts treated with 21 Gy (Table) 
Conclusions: High dose of 21 Gy for patients undergoing VBT with gamma radiation is
associated with less recurrences compared to the approved radiation dose without
increase of adverse events. Thus, optimization of the dose should be considered for pts
undergoing VBT for ISR.
11:45 a.m.
880-6 Three-Year Follow-Up After Intracoronary Gamma 
Radiation for In-Stent Restenosis in Saphenous Vein 
Grafts
Seung-Woon Rha, Ron Waksman, Pramod K. Kuchulakanti, Andrew E. Ajani, Larry R. 
White, Daniel A. Canos, Edouard Cheneau, Verne Mattox, Maureen C. Abbott, Ellen 
Pinnow, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, 
Washington Hospital Center, Washington, DC
Background: The Washington Radiation for In-Stent Restenosis Trial in saphenous vein
grafts (SVG WRIST) demonstrated safety and efficacy of intracoronary gamma radiation
for the treatment of in-stent restenosis (ISR) in saphenous vein grafts (SVG) at 6 months.
The aim of this study was to examine whether the results reported at 6 months continued
to be durable at 36 months.
Methods: One hundred and twenty patients (pts) with ISR in SVG underwent PTCA,
laser ablation, rotational atherectomy, and/or additional stenting (36% of lesions). Pts
were randomized to either 192Ir IRT or placebo, with a prescribed dose of 15 Gy or 18 Gy
to a 2 mm radial distance from the center of the source. Pts were followed angiographi-
cally at 6 months and clinically up to 36 months.
Results: Angiographic restenosis (21 %vs. 44%, p=0.005) and target vessel revascular-
ization [TVR, (18 % vs. 55%, p<0.001)] were dramatically reduced at 6 months in intrac-
oronary radiation therapy (IRT) pts. At 12 months, IRT compared to placebo pts had less
target lesion revascularization [TLR, (17% vs.57%, p<0.001)] and TVR (28% vs. 62%,
p<0.001). At 36 months clinical follow-up, pts receiving IRT continued to have markedly
lower MACE rates when compared with controls (Table).
Conclusions: In SVG WRIST, pts with ISR treated with IRT using 192Ir had a marked
reduction in the need for repeat target lesion and vessel revascularization at 6 months,
with durability of the clinical benefit at three years.
Table. Twelve and 36-Month Clinical Outcomes 
14Gy 1M 
(N=120) 
14Gy 6M 
(N=120) 
18Gy 1M 
(N=120) 
18Gy 6M 
(N=120) 
21Gy 1M 
(N=31) 
21Gy 6M 
(N=12) 
Death, % 0 1.7 0 0 0 0
Q-Wave 
MI, %
0 0.8 0 0.9 0 0
TLR, % 0.8 20.8 2.5 16.5 0 8.3
TVR, % 16.7 25 4.6 22.9 0 25
Late 
Thrombos
is
0.8 1.7 0.9 6.4 0 0
12 Months (%) 36 Months (%)
Events Ir-192 
(N=60)
Placebo 
(N=60)
P-
Value
Ir-192 
(N=60)
Placebo 
(N=60)
P-
Value
Death 7 7 1.0 17 10 0.283
Q-wave 
MI
2 3 1.0 3 2 0.559
TVR 28 62 <0.001 47 65 0.043
TLR 17 57 <0.001 33 60 0.003
All MACE 23 57 <0.001 38 63 0.006
